Literature DB >> 28450037

Prognostic Impact of Age and Hemoglobin in Acute ST-Segment Elevation Myocardial Infarction Treated With Reperfusion Therapy.

Jesús Velásquez-Rodríguez1, Felipe Diez-Delhoyo1, María Jesús Valero-Masa1, Lourdes Vicent1, Carolina Devesa1, Iago Sousa-Casasnovas1, Miriam Juárez1, Rocío Angulo-Llanos1, Francisco Fernández-Avilés2, Manuel Martínez-Sellés3.   

Abstract

Advanced age and low hemoglobin levels have been associated with a poor prognosis in ST-segment elevation myocardial infarction (STEMI). We studied 1,111 patients with STEMI who received reperfusion treatment (1,032 [92.9%] primary angioplasty and 79 [7.1%] fibrinolysis without rescue percutaneous coronary intervention). Mean age was 64.1 ± 14.0 years, and 23.2% were women. Patients in the last age quartile (>76 years) were more frequently women, presented more risk factors (except smoking), received thrombolysis less frequently, had less complete revascularization, and presented more complications and higher mortality. Hemoglobin level at admission was associated with age and ranged from 14.8 ± 1.5 g/dl in the first quartile to 13.2 ± 1.8 g/dl in the last, p <0.001. Multivariate analysis identified age as a predictor of in-hospital and long-term mortality (odds ratio 1.04, 95% confidence interval [CI] 1.00 to 1.07, hazard ratio 1.06, 95% CI 1.04 to 1.08). Hemoglobin levels were associated with better survival (odds ratio 0.8, 95% CI 0.6 to 0.9, hazard ratio 0.85, 95% CI 0.78 to 0.92). The other predictors of inhospital mortality were Killip class, chronic kidney disease, left ventricular ejection fraction, significant pericardial effusion, and ventricular arrhythmias. The association of hemoglobin with hospital mortality was seen in men and in women ≥65 years. In men ≥65 years, this association was also present in those with hemoglobin levels in the normal range. In conclusion, in patients with STEMI, hemoglobin is an independent predictor of inhospital and long-term mortality, especially in those aged ≥65 years. This association is also present in men ≥65 years with normal hemoglobin levels.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28450037     DOI: 10.1016/j.amjcard.2017.03.018

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Predictive value of SYNTAX score II for clinical outcomes in cardiogenic shock underwent primary percutaneous coronary intervention; a pilot study.

Authors:  Mert İlker Hayıroğlu; Muhammed Keskin; Ahmet Okan Uzun; Emrah Bozbeyoğlu; Özlem Yıldırımtürk; Ömer Kozan; Seçkin Pehlivanoğlu
Journal:  Int J Cardiovasc Imaging       Date:  2017-09-09       Impact factor: 2.357

2.  A retrospective study of an invasive versus conservative strategy in patients aged ≥80 years with acute ST-segment elevation myocardial infarction.

Authors:  Yong-Gang Sui; Si-Yong Teng; Jie Qian; Yuan Wu; Ke-Fei Dou; Yi-Da Tang; Shu-Bin Qiao; Yong-Jian Wu
Journal:  J Int Med Res       Date:  2019-07-26       Impact factor: 1.671

3.  Association between serum hemoglobin and major cardiovascular adverse event in Chinese patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention.

Authors:  Yulu Yang; Yun Huang
Journal:  J Clin Lab Anal       Date:  2021-12-10       Impact factor: 2.352

4.  Association of In-Hospital Hemoglobin Drop With Decreased Myocardial Salvage and Increased Long-Term Mortality in Patients With Acute ST-Segment-Elevation Myocardial Infarction.

Authors:  Alexander Dutsch; Christian Graesser; Felix Voll; Sophie Novacek; Robert Eggerstedt; Nicolás López Armbruster; Karl-Ludwig Laugwitz; Salvatore Cassese; Heribert Schunkert; Gjin Ndrepepa; Adnan Kastrati; Thorsten Kessler; Hendrik B Sager
Journal:  J Am Heart Assoc       Date:  2022-08-24       Impact factor: 6.106

5.  Elderly Suffering from ST-Segment Elevation Myocardial Infarction-Results from a Database Analysis from Two Mediterranean Medical Centers.

Authors:  Leor Perl; Alfonso Franzé; Fabrizio D'Ascenzo; Noa Golomb; Amos Levi; Hana Vaknin-Assa; Gabriel Greenberg; Abid Assali; Gaetano M De Ferrari; Ran Kornowski
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.